JP2009511905A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511905A5
JP2009511905A5 JP2008535546A JP2008535546A JP2009511905A5 JP 2009511905 A5 JP2009511905 A5 JP 2009511905A5 JP 2008535546 A JP2008535546 A JP 2008535546A JP 2008535546 A JP2008535546 A JP 2008535546A JP 2009511905 A5 JP2009511905 A5 JP 2009511905A5
Authority
JP
Japan
Prior art keywords
alzheimer
disease
cell
subject
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008535546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511905A (ja
JP4908514B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2005/036014 external-priority patent/WO2007043998A1/en
Priority claimed from US11/246,524 external-priority patent/US7595167B2/en
Priority claimed from PCT/US2006/022156 external-priority patent/WO2007044094A1/en
Application filed filed Critical
Priority claimed from PCT/US2006/037186 external-priority patent/WO2007047029A2/en
Publication of JP2009511905A publication Critical patent/JP2009511905A/ja
Publication of JP2009511905A5 publication Critical patent/JP2009511905A5/ja
Application granted granted Critical
Publication of JP4908514B2 publication Critical patent/JP4908514B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008535546A 2005-10-11 2006-09-25 アルツハイマー病に特異的なerk1/erk2リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー(adsmb) Expired - Fee Related JP4908514B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2005/036014 WO2007043998A1 (en) 2005-10-11 2005-10-11 Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
US11/246,524 US7595167B2 (en) 2005-10-11 2005-10-11 Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US11/246,524 2005-10-11
USPCT/US2005/036014 2005-10-11
USPCT/US2006/022156 2006-06-07
PCT/US2006/022156 WO2007044094A1 (en) 2005-10-11 2006-06-07 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
PCT/US2006/037186 WO2007047029A2 (en) 2005-10-11 2006-09-25 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)

Publications (3)

Publication Number Publication Date
JP2009511905A JP2009511905A (ja) 2009-03-19
JP2009511905A5 true JP2009511905A5 (https=) 2009-11-12
JP4908514B2 JP4908514B2 (ja) 2012-04-04

Family

ID=37067652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008535546A Expired - Fee Related JP4908514B2 (ja) 2005-10-11 2006-09-25 アルツハイマー病に特異的なerk1/erk2リン酸化比の変化−アルツハイマー病に特異的な分子生物マーカー(adsmb)

Country Status (10)

Country Link
US (1) US20180024146A1 (https=)
EP (5) EP2322936A1 (https=)
JP (1) JP4908514B2 (https=)
KR (2) KR20140002073A (https=)
AT (1) ATE431558T1 (https=)
CA (1) CA2625300C (https=)
DE (1) DE602006006855D1 (https=)
ES (5) ES2412268T3 (https=)
TW (2) TW201413246A (https=)
WO (1) WO2007044094A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1549721B (zh) 2001-02-27 2012-03-07 布朗歇特洛克菲勒神经科学研究所 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
CN103961347A (zh) * 2006-07-28 2014-08-06 布朗歇特洛克菲勒神经科学研究所 刺激细胞生长、突触重塑和巩固长期记忆的方法
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
EP2669386A1 (en) 2008-07-28 2013-12-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
WO2010014585A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
BRPI0914859A2 (pt) * 2008-08-27 2015-11-03 Lundbeck & Co As H método para diagnosticar um distúrbio afetivo, produto de programa de computador, computador, e, método para determinar uma probabilidade de que um indivíduo de teste exiba um sintoma de um distúrbio afetivo
US8658134B2 (en) 2009-10-02 2014-02-25 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of Alzheimer's disease
JP6013184B2 (ja) * 2009-10-02 2016-10-25 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病末梢細胞におけるpkcアイソザイムプロセッシングの異常変化
CA2835686C (en) * 2011-05-12 2019-10-01 Florin V. Chirila Peripheral diagnostic methods for screening alzheimer's disease using beta amyloid and intercellular communication
EP2780316B1 (en) 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
KR101351978B1 (ko) * 2012-10-30 2014-01-16 주식회사 코씨드바이오팜 참치 안구 파쇄물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
CA2935266C (en) * 2014-01-03 2022-02-01 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
US11415574B2 (en) 2017-03-31 2022-08-16 NeuroDiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
WO2020237203A1 (en) * 2019-05-23 2020-11-26 Indiana University Research And Technology Corporation Methods for objective assessment of memory, early detection of risk for alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US20030108956A1 (en) * 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
CN1549721B (zh) * 2001-02-27 2012-03-07 布朗歇特洛克菲勒神经科学研究所 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
KR100574017B1 (ko) 2003-08-11 2006-04-26 삼성전자주식회사 잉크젯 프린터의 잉크 카트리지
US7199386B2 (en) 2004-07-29 2007-04-03 General Electric Company System and method for detecting defects in a light-management film

Similar Documents

Publication Publication Date Title
JP2009511905A5 (https=)
Hu et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay
Wu et al. Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition risk outcomes in liver cirrhosis patients compared with Nutritional Risk Screening 2002
AU2010291933B2 (en) Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
CN102762986B (zh) 阿尔茨海默病的诊断方法
WO2007062090A8 (en) Methods and compositions related to b cell assays
EP2322932A3 (en) Detection of tuberculosis and infection by mycobacterium tuberculosis using HBHA
DE60235746D1 (de) Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
JP5677297B2 (ja) 神経変性疾患の診断/予後判定の指標としてのグルタミニルシクラーゼ
JP2009529884A5 (https=)
Lima et al. Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression
US20150160240A1 (en) Host Biomarkers for Dengue Fever (DF) and Methods Thereof
Liu et al. Genetic screening and functional analysis of CASP 9 mutations in a Chinese cohort with neural tube defects
WO2005019471A3 (en) Periostin-like factor: compositions and methods for making and using the same
RU2008123385A (ru) Способы диагностики заболеваний печени и скрининга молекул для лечения этих заболеваний
MX2013002820A (es) Estraficacion de pacientes con cancer para determinar la susceptibilidad al tratamiento con inhibidores de ptk2.
Byun et al. Deubiquitinase USP2 promotes hepatic stellate cell activation via p300 stabilization
Di Napoli et al. Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon
RU2830412C1 (ru) Способ прогнозирования риска развития дыхательной недостаточности у больных с внебольничной пневмонией на фоне инфицирования SARS-CoV2
JP2008506416A5 (https=)
RU2006124937A (ru) Способ прогнозирования течения сахарного диабета 1 типа
Alavian et al. Commentary on “risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States”
Harrell et al. 4) INFECTED CELL PROTEIN 0 (ICP0) MODULATES HOST CELL HOMEOSTASIS DURING LATENCY IN PRIMARY ADULT NEURONS
JP2010507780A5 (https=)